Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T vs DLI for MRD in Ph-Negative B-ALL After HSCT
NCT07441291Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 3 trial of Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital) in acute lymphoblastic leukemia (ALL), sponsored by Peking University People's Hospital. Started Nov 2025; status: recruiting.
02
Drugs
Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital)
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07441291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441291.